title: Octreotide: an active agent in epithelial ovarian carcinoma?
authors.affiliation: Cancer Research UK Molecular Oncology Group, Department of Pathology and Microbiology, School of Medical Sciences, Bristol, UK. Rob.Jones@bristol.ac.uk
authors.forename: Robert H
authors.initials: RH
authors.lastname: Jones
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Reubi
authors.forename: David
authors.initials: D
authors.lastname: Millan
authors.forename: Paul
authors.initials: P
authors.lastname: Vasey
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000032:analysis; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000150:complications; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017481:Receptors, Somatostatin / Q000032:analysis; D012075:Remission, Spontaneous; D014839:Vomiting / Q000188:drug therapy
chemical_list: D018931:Antineoplastic Agents, Hormonal; D018394:CA-125 Antigen; D017481:Receptors, Somatostatin; D015282:Octreotide